시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 섬유근육통 디지털 치료제 시장 보고서(2025년)
Digital Therapeutics For Fibromyalgia Global Market Report 2025
상품코드 : 1877612
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,693,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,675,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,656,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 섬유근육통 디지털 치료제 시장 규모는 최근 급격히 확대되고 있습니다. 2024년 9억 8,000만 달러에서 2025년에는 11억 9,000만 달러로 확대되고, CAGR 21.3%로 성장이 전망되고 있습니다. 이 성장은 섬유근육통의 임상적 인지도 향상과 조기 진단의 진전, 신형 코로나 바이러스 팬데믹 하에서 재택 자기 관리로의 전환, 보험 회사 및 고용주에 의한 비 약물치료 통증 관리의 선호, 행동 요법적 통증 치료를 지원하는 오피오이드 적정 사용 방침, 저위험이고 비약물적인 통증 개입법에 대한 환자 선호 증가 등의 요인에 기인하고 있습니다.

섬유근육통 디지털 치료제 시장 규모는 향후 수년간 급격한 성장이 예상됩니다. 2029년까지 25억 4,000만 달러에 달하고 CAGR은 20.9%가 될 전망입니다. 예측기간 중 성장요인으로는 증거 기반 디지털 개입에 대한 상환 범위 확대, 류마티스학 및 1차 케어 경로로의 통합 진전, 고령화에 따른 유병률과 증상 부담 증가, 여성의 건강과 만성 통증의 형평성 중시가 높아져 불필요한 영상 진단이나 진찰을 삭감하는 비용 억제 압박 등이 있습니다. 예측기간의 주요 동향으로는 수용과 헌신요법 프로그램을 제공하는 처방 디지털 치료제, 가상현실(VR) 기반의 통증 분산 및 재활 모듈, 증강현실(AR) 가이드 부착 운동 요법 및 자세 훈련, 인공지능(AI)에 의한 치료 내용 및 페이스의 개별화, 자연 언어 처리(NLP)를 활용한 코치 등이 있습니다.

디지털 헬스 솔루션에 대한 인지도 향상은 향후 수년간 섬유근육통 디지털 치료제 시장의 성장을 이끌 것으로 예측됩니다. 디지털 헬스 솔루션에는 환자용 앱, 환자 포털, 가상 케어 플랫폼 등 디지털 채널을 통해 정보 제공, 모니터링 및 치료를 제공하는 소프트웨어 지원 도구 및 서비스가 포함됩니다. 이 인지도 향상은 정부 지원 이니셔티브 및 공식 건강 앱의 보급으로 촉진되고 있으며 온라인 의료 액세스가 일반화되고 있습니다. 섬유근육통 디지털 치료제는 이러한 친숙한 채널을 활용하여 앱 기반의 인지 행동 치료, 페이스 관리, 수면 프로그램의 도입과 지속을 효율화하는 동시에 임상의에 의한 감시를 가능하게 합니다. 예를 들어, 2023년 12월에 영국 국민보건서비스(NHS)가 보고한 바에 따르면 디지털 헬스 앱 이용자수는 2022년 1,680만명에서 3,360만명으로, 월간 로그인수는 1,680만명에서 2,580만명으로 54% 증가했습니다. 이는 디지털 건강 솔루션에 대한 인지도 향상이 어떻게 섬유근육통 디지털 치료제 시장을 추진하는지를 보여줍니다.

섬유근육통 디지털 치료제 시장의 주요 기업은 컴퓨터화된 행동 치료 장치 등의 기술적 진보에 주력하고, 확장 가능하고 환자 중심의 디지털 플랫폼을 통해 통증 관리 개선, 피로 경감, 수면 질 향상, 정신 건강 지원 등 근거 기반 개입을 제공합니다. 컴퓨터화된 행동 치료 장치는 소프트웨어 기반 플랫폼 또는 애플리케이션으로, 대화형 모듈, 운동, 실시간 피드백을 활용하고 구조화된 증거를 기반으로 인지 치료 또는 행동 치료를 원격으로 제공하여 섬유근육통의 증상을 관리합니다. 예를 들어 2023년 5월에는 미국 Swing Therapeutics사가 미국 FDA의 데노보 승인(DEN220083)을 취득한 후 Stanza를 출시했습니다. 본 프로그램은 섬유근육통을 위한 12주간 자기관리형 ACT(수용 및 헌신요법) 프로그램을 제공하며, 랜덤화 비교시험에 의해 'The Lancet'에서 보고된 임상적 개선이 인정되었습니다. 스마트폰(iOS 또는 Android)을 통해 제공되므로 환자는 집에서 편리하게 치료에 접근할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Digital therapeutics for fibromyalgia are health applications and online programs that provide structured therapy and monitor symptoms to support daily self-management. They aim to reduce pain and fatigue, enhance sleep and functionality, and offer patients and clinicians valuable data for personalized care.

The primary product types of digital therapeutics for fibromyalgia include software applications, devices, and platforms. Software applications are clinically validated programs designed to deliver therapeutic interventions for managing fibromyalgia symptoms such as pain and fatigue. These solutions are available through both online and offline channels. Key applications include chronic pain management, sleep disorder management, fatigue management, and others, with main end users being hospitals, clinics, homecare providers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The digital therapeutics for fibromyalgia market research report is one of a series of new reports from The Business Research Company that provides digital therapeutics for fibromyalgia market statistics, including the digital therapeutics for fibromyalgia industry global market size, regional shares, competitors with the digital therapeutics for fibromyalgia market share, detailed digital therapeutics for fibromyalgia market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics for fibromyalgia industry. This digital therapeutics for fibromyalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The digital therapeutics for fibromyalgia market size has grown exponentially in recent years. It will grow from $0.98 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 21.3%. The growth during the historic period is attributed to increasing clinical recognition of fibromyalgia and earlier diagnosis, a shift toward home-based self-management during the coronavirus pandemic, insurer and employer preference for nonpharmacological pain management, opioid stewardship policies supporting behavioral pain therapies, and rising patient preference for low-risk, non-drug pain interventions.

The digital therapeutics for fibromyalgia market size is expected to see exponential growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 20.9%. The growth during the forecast period is attributed to the expansion of reimbursement for evidence-based digital interventions, increasing integration into rheumatology and primary care pathways, rising prevalence and symptom burden in aging populations, greater emphasis on women's health and chronic pain equity, and cost-containment pressures to reduce unnecessary imaging and visits. Key trends in the forecast period include prescription digital therapeutics providing acceptance and commitment therapy programs, virtual reality-based pain distraction and rehabilitation modules, augmented reality-guided movement therapy and posture training, artificial intelligence-driven personalization of therapy content and pacing, and natural language processing-powered coaching and symptom triage.

The increasing awareness of digital health solutions is expected to drive the growth of the digital therapeutics for fibromyalgia market in the coming years. Digital health solutions include software-enabled tools and services such as patient apps, patient portals, and virtual-care platforms that provide information, monitoring, and therapy through digital channels. This growing awareness is fueled by government-supported initiatives and widespread adoption of official health apps that normalize online access to care. Digital therapeutics for fibromyalgia leverage these familiar channels to streamline onboarding and adherence to app-based cognitive behavioral therapy, pacing, and sleep programs while allowing clinician oversight. For example, in December 2023, the UK National Health Service reported that digital health app users reached 33.6 million, up from 16.8 million in 2022, with monthly logins increasing 54% from 16.8 million to 25.8 million. This demonstrates how increasing awareness of digital health solutions is propelling the digital therapeutics for fibromyalgia market.

Key companies in the digital therapeutics for fibromyalgia market are focusing on technological advancements, such as computerized behavioral therapy devices, to deliver evidence-based interventions that improve pain management, reduce fatigue, enhance sleep quality, and support mental health through scalable, patient-centric digital platforms. A computerized behavioral therapy device is a software-based platform or application that provides structured, evidence-based cognitive or behavioral therapy interventions remotely, using interactive modules, exercises, and real-time feedback to manage fibromyalgia symptoms. For instance, in May 2023, US-based Swing Therapeutics, Inc. launched Stanza following U.S. FDA De Novo marketing authorization (DEN220083). The program offers a 12-week, self-guided acceptance and commitment therapy (ACT) program for fibromyalgia, with a randomized controlled trial in The Lancet reporting significant clinical improvements. It is delivered via smartphone (iOS or Android), allowing patients to access therapy conveniently at home.

In February 2025, US-based XRHealth Inc., a therapeutic extended reality (XR) and digital therapeutics company, acquired RealizedCare for an undisclosed amount. Through this acquisition, XRHealth aims to integrate RealizedCare's immersive digital therapeutics content and artificial intelligence triage tool into its platform to expand evidence-based care for chronic pain and behavioral health, including its existing fibromyalgia programs, while scaling AI-enabled, value-based delivery and enhancing clinician oversight and personalization. RealizedCare is a US-based immersive digital therapeutics company specializing in chronic pain and behavioral health.

Major players in the digital therapeutics for fibromyalgia market are Grunenthal GmbH, Hinge Health Inc., DarioHealth Corp., Kaia Health, CogniFit Inc., Big Health Ltd., Remedee Labs, HelloBetter GmbH, AppliedVR Inc., PainDrainer, Swing Therapeutics Inc., Fern Health Inc., JOGO Health Inc., LIN Health Inc., MoreGoodDays, Happify Health Inc., Click Therapeutics Inc., Wellthy Therapeutics Pvt. Ltd., FlexifyMe, SleepioRx.

North America was the largest region in the digital therapeutics for fibromyalgia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Digital Therapeutics For Fibromyalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics for fibromyalgia market consists of revenues earned by entities by providing services such as remote health coaching and therapist support, tele-physiotherapy consultations, adherence and engagement services, and outcomes analytics and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics for fibromyalgia market also includes sales of cognitive behavioral therapy (cbt) apps, pain neuroscience education modules, digital graded exercise and activity pacing programs, virtual reality-based pain distraction experiences, and sleep hygiene and relaxation programs, clinician dashboards and care coordination tools, patient. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Digital Therapeutics For Fibromyalgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on digital therapeutics for fibromyalgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for digital therapeutics for fibromyalgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital therapeutics for fibromyalgia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Digital Therapeutics For Fibromyalgia Market Characteristics

3. Digital Therapeutics For Fibromyalgia Market Trends And Strategies

4. Digital Therapeutics For Fibromyalgia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Digital Therapeutics For Fibromyalgia Growth Analysis And Strategic Analysis Framework

6. Digital Therapeutics For Fibromyalgia Market Segmentation

7. Digital Therapeutics For Fibromyalgia Market Regional And Country Analysis

8. Asia-Pacific Digital Therapeutics For Fibromyalgia Market

9. China Digital Therapeutics For Fibromyalgia Market

10. India Digital Therapeutics For Fibromyalgia Market

11. Japan Digital Therapeutics For Fibromyalgia Market

12. Australia Digital Therapeutics For Fibromyalgia Market

13. Indonesia Digital Therapeutics For Fibromyalgia Market

14. South Korea Digital Therapeutics For Fibromyalgia Market

15. Western Europe Digital Therapeutics For Fibromyalgia Market

16. UK Digital Therapeutics For Fibromyalgia Market

17. Germany Digital Therapeutics For Fibromyalgia Market

18. France Digital Therapeutics For Fibromyalgia Market

19. Italy Digital Therapeutics For Fibromyalgia Market

20. Spain Digital Therapeutics For Fibromyalgia Market

21. Eastern Europe Digital Therapeutics For Fibromyalgia Market

22. Russia Digital Therapeutics For Fibromyalgia Market

23. North America Digital Therapeutics For Fibromyalgia Market

24. USA Digital Therapeutics For Fibromyalgia Market

25. Canada Digital Therapeutics For Fibromyalgia Market

26. South America Digital Therapeutics For Fibromyalgia Market

27. Brazil Digital Therapeutics For Fibromyalgia Market

28. Middle East Digital Therapeutics For Fibromyalgia Market

29. Africa Digital Therapeutics For Fibromyalgia Market

30. Digital Therapeutics For Fibromyalgia Market Competitive Landscape And Company Profiles

31. Digital Therapeutics For Fibromyalgia Market Other Major And Innovative Companies

32. Global Digital Therapeutics For Fibromyalgia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Digital Therapeutics For Fibromyalgia Market

34. Recent Developments In The Digital Therapeutics For Fibromyalgia Market

35. Digital Therapeutics For Fibromyalgia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기